Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults
David Gómez-Almaguer, Miguel A Herrera-Rojas, José C Jaime-Pérez, Andrés Gómez-De León, Olga G Cantú-Rodríguez, César H Gutiérrez-Aguirre, Luz Tarín-Arzaga, Jesús Hernández-Reyes, Guillermo J Ruiz-Arguelles, David Gómez-Almaguer, Miguel A Herrera-Rojas, José C Jaime-Pérez, Andrés Gómez-De León, Olga G Cantú-Rodríguez, César H Gutiérrez-Aguirre, Luz Tarín-Arzaga, Jesús Hernández-Reyes, Guillermo J Ruiz-Arguelles
Abstract
Immune thrombocytopenia (ITP) results from platelet destruction and production suppression. Eltrombopag belongs to a new class of thrombopoietin-mimetic drugs that raise platelet counts in ITP patients. We performed a single-arm study to assess the response to a single course of dexamethasone (40 mg by mouth, days 1-4) in combination with eltrombopag (50 mg, days 5-32) in 12 adults with newly diagnosed ITP in an outpatient setting. Median follow-up was 12.5 months. After therapy (day 33), 100% of patients achieved at least ≥30 × 10(9)/L platelets. Four patients relapsed. Complete response at 6 months (platelets ≥100 × 10(9)/L) was achieved in 50% of patients and response at 6 months (platelets ≥30 <100 × 10(9)/L) was achieved in another 25%; relapse-free survival was 66.7% at 12 months (median response duration of 8.3 months). In conclusion, eltrombopag/dexamethasone is a feasible frontline therapy for ITP. This trial is registered at www.clinicaltrials.gov as NCT01652599.
© 2014 by The American Society of Hematology.
Source: PubMed